{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:51:37Z","timestamp":1781725897404,"version":"3.54.5"},"reference-count":100,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK129721 and K23DK115894."],"award-info":[{"award-number":["K23DK129721 and K23DK115894."]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>Childhood obesity affects nearly one in five children in the U.S. and is a key driver in youth-onset type 2 diabetes (T2D) development and progression. Effective obesity treatment may lead to T2D remission and can greatly improve dysglycemia and insulin sensitivity. The main objective of this article is to describe the growing evidence in support of targeting obesity to treat T2D in youth. There is growing evidence and guidance that for adults with T2D medical and surgical treatments for obesity should be prioritized. Yet, for youth with T2D, there has been limited movement to prioritize treating obesity, despite its role in diabetes pathophysiology. In adults, addition of obesity medications and bariatric surgery to the diabetes treatment regimen results in substantial weight reduction, improvement in dysglycemia, and decreased use of diabetes agents. In youth, there is limited, yet mounting evidence of these same benefits. U.S. Food and Drug Administration\u2013approved obesity medications are effective and well tolerated in youth with obesity and an important therapeutic tool for youth with T2D and obesity. For several medications clinically significant weight reduction has been demonstrated, with improvement in insulin resistance and dysglycemia. In youth with T2D significant weight reduction has been demonstrated with bariatric surgery, with significant 3- and 10-year diabetes remission rates. Further studies in pediatric patients with T2D and obesity are needed to determine the long-term impacts of obesity therapies and bariatric surgery on progression and outcomes of youth-onset T2D.<\/jats:p>","DOI":"10.2337\/dci25-0031","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:35:15Z","timestamp":1753828515000},"page":"1981-1993","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-1858","authenticated-orcid":false,"given":"Megan O.","family":"Bensignor","sequence":"first","affiliation":[{"name":"Center for Pediatric Obesity Medicine, University of Minnesota 1 , Minneapolis, MN"},{"name":"Department of Pediatric Endocrinology and Diabetes, University of Minnesota Medical School 2 , Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hsia","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, and Children\u2019s Healthcare of Atlanta 3 , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Van Name","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine 4 , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania M.","family":"Jastreboff","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine 4 , New Haven, CT"},{"name":"Endocrinology and Metabolism, Department of Medicine, Yale School of Medicine 5 , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-9497","authenticated-orcid":false,"given":"Justin R.","family":"Ryder","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago 6 , Chicago, IL"},{"name":"Department of Surgery, Northwestern Feinberg School of Medicine 7 , Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2026061714573851500_B1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jama.2020.14590","article-title":"Trends in obesity prevalence by race and Hispanic origin-1999-2000 to 2017-2018","volume":"324","author":"Ogden","year":"2020","journal-title":"JAMA"},{"key":"2026061714573851500_B2","unstructured":"Centers for Disease Control and Prevention\n          . National Diabetes Statistics Report, 2020: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA, Centers for Disease Control and Prevention, 2020"},{"key":"2026061714573851500_B3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpeds.2022.08.010","article-title":"The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes","volume":"251","author":"Magge","year":"2022","journal-title":"J Pediatr"},{"key":"2026061714573851500_B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/pedi.12981","article-title":"Clinical profile at diagnosis with youth-onset type 1 and type 2 diabetes in two pediatric diabetes registries: SEARCH (United States) and YDR (India)","volume":"22","author":"Hockett","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"2026061714573851500_B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"2026061714573851500_B6","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1210\/clinem\/dgae004","article-title":"DXA-based fat mass with risk of worsening insulin resistance in adolescents: a 9-year temporal and mediation study","volume":"109","author":"Agbaje","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714573851500_B7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2337\/dc18-0243","article-title":"Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test","volume":"41","author":"The RISE Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc21-0027","article-title":"Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) Study","volume":"44","author":"Sam","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ijpo.12148","article-title":"Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience","volume":"12","author":"Marcus","year":"2017","journal-title":"Pediatr Obes"},{"key":"2026061714573851500_B11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/2013.jamapediatrics.319","article-title":"Response of severely obese children and adolescents to behavioral treatment","volume":"166","author":"Danielsson","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2026061714573851500_B12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"Zeitler","year":"2012","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/pedi.13279","article-title":"A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes","volume":"23","author":"Shankar","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026061714573851500_B14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061714573851500_B15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"2026061714573851500_B16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B17","doi-asserted-by":"crossref","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"2026061714573851500_B18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa2100165","article-title":"Long-term complications in youth-onset type 2 diabetes","volume":"385","author":"Bjornstad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/dc24-2459","article-title":"Persistent hyperglycemia and insulin resistance with the risk of worsening cardiac damage in adolescents: a 7-year longitudinal study of the ALSPAC birth cohort","volume":"48","author":"Agbaje","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/dmrr.2501","article-title":"Incretins: their physiology and application in the treatment of diabetes mellitus","volume":"30","author":"Tasyurek","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"2026061714573851500_B21","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B23","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2337\/dc21-2275","article-title":"Once-weekly exenatide in youth with type 2 diabetes","volume":"45","author":"Tamborlane","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B25","doi-asserted-by":"crossref","first-page":"e12778","DOI":"10.1111\/ijpo.12778","article-title":"Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: post hoc analysis of the ellipse trial","volume":"16","author":"Bensignor","year":"2021","journal-title":"Pediatr Obes"},{"key":"2026061714573851500_B26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/dia.2013.0366","article-title":"Liraglutide\u2019s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Klein","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"2026061714573851500_B27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-014-0171-2","article-title":"Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes","volume":"14","author":"Blonde","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2026061714573851500_B28","unstructured":"U.S. Food and Drug Administration\n          . FDA Approves Weight Management Drug for Patients Aged 12 and Older,2020. Accessed 14 September 2021. Available from https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-weight-management-drug-patients-aged-12-and-older"},{"key":"2026061714573851500_B29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B30","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1210\/jendso\/bvac150.002","article-title":"LBODP002 phase II open-label pilot trial of liraglutide in adolescents with obesity after vertical sleeve gastrectomy: interim results from 8-weeks of treatment","volume":"6","author":"Fatima","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026061714573851500_B31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to &lt;12 years of age with obesity - a randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B32","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B33","unstructured":"U.S. Food and Drug Administration\n          . FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, 2024. Accessed 16 January 2025. Available from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"2026061714573851500_B34","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"2026061714573851500_B35","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.","year":"2012"},{"key":"2026061714573851500_B36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"key":"2026061714573851500_B37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ijo.2016.185","article-title":"Effect of phentermine on weight reduction in a pediatric weight management clinic","volume":"41","author":"Ryder","year":"2017","journal-title":"Int J Obes (Lond)"},{"key":"2026061714573851500_B38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/oby.22385","article-title":"Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity","volume":"27","author":"Srivastava","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"2026061714573851500_B39","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1528-1167.2010.02598.x","article-title":"Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to &lt;10 years of age","volume":"51","author":"Girgis","year":"2010","journal-title":"Epilepsia"},{"key":"2026061714573851500_B40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fped.2020.00028","article-title":"The efficacy and safety of topiramate in the prevention of pediatric migraine: an update meta-analysis","volume":"8","author":"Wu","year":"2020","journal-title":"Front Pediatr"},{"key":"2026061714573851500_B41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"2026061714573851500_B42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2026061714573851500_B43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/chi.2022.0062","article-title":"Topiramate for weight management in children with severe obesity","volume":"19","author":"Berman","year":"2023","journal-title":"Child Obes"},{"key":"2026061714573851500_B44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0009922814542481","article-title":"Topiramate for weight reduction in adolescents with severe obesity","volume":"54","author":"Fox","year":"2015","journal-title":"Clin Pediatr (Phila)"},{"key":"2026061714573851500_B45","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/oby.21633","article-title":"Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial","volume":"24","author":"Fox","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"2026061714573851500_B46","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2026061714573851500_B48","doi-asserted-by":"crossref","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","author":"Kelly","DOI":"10.1056\/EVIDoa2200014"},{"key":"2026061714573851500_B49","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.obpill.2024.100099","article-title":"Effects of phentermine \/ topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: a randomized, multicenter, double-blind study","volume":"9","author":"Bays","year":"2024","journal-title":"Obes Pillars"},{"key":"2026061714573851500_B50","doi-asserted-by":"crossref","first-page":"2042018820918789","DOI":"10.1177\/2042018820918789","article-title":"Medications for the treatment of obesity in adolescents","volume":"11","author":"Woodard","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026061714573851500_B51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/JPEM.2004.17.3.307","article-title":"Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions","volume":"17","author":"McDuffie","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026061714573851500_B52","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"2026061714573851500_B53","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B54","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","article-title":"A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin","volume":"22","author":"Berne","year":"2005","journal-title":"Diabet Med"},{"key":"2026061714573851500_B55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1506699","article-title":"Weight loss and health status 3 years after bariatric surgery in adolescents","volume":"374","author":"Inge","year":"2016","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B56","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMc2404054","article-title":"Ten-year outcomes after bariatric surgery in adolescents","volume":"391","author":"Ryder","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ijo.2015.174","article-title":"Changes in inflammation, oxidative stress and adipokines following bariatric surgery among adolescents with severe obesity","volume":"40","author":"Kelly","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"2026061714573851500_B58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"key":"2026061714573851500_B59","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1056\/NEJMoa1813909","article-title":"Five-year outcomes of gastric bypass in adolescents as compared with adults","volume":"380","author":"Inge","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B60","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamapediatrics.2017.5763","article-title":"Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents","volume":"172","author":"Inge","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2026061714573851500_B61","doi-asserted-by":"crossref","first-page":"e20201610","DOI":"10.1542\/peds.2020-1610","article-title":"Efficacy and safety of metformin for obesity: a systematic review","volume":"147","author":"Masarwa","year":"2021","journal-title":"Pediatrics"},{"key":"2026061714573851500_B62","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bcp.2011.11.028","article-title":"DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"83","author":"Duez","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2026061714573851500_B63","doi-asserted-by":"crossref","first-page":"EVIDoa2300210","DOI":"10.1056\/EVIDoa2300210","article-title":"Dapagliflozin or saxagliptin in pediatric type 2 diabetes","volume":"2","author":"Shehadeh","year":"2023","journal-title":"NEJM Evid"},{"key":"2026061714573851500_B64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s13300-025-01700-3","article-title":"A randomized phase 3 study evaluating the efficacy and safety of alogliptin in pediatric participants with type 2 diabetes mellitus","volume":"16","author":"Peng","year":"2025","journal-title":"Diabetes Ther"},{"key":"2026061714573851500_B65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/pedi.13282","article-title":"Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin","volume":"23","author":"Jalaludin","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026061714573851500_B66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diabet.2018.01.017","article-title":"Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Mishriky","year":"2018","journal-title":"Diabetes Metab"},{"key":"2026061714573851500_B67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026061714573851500_B68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061714573851500_B69","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2337\/dc16-1203","article-title":"BMI at age 17 years and diabetes mortality in midlife: a nationwide cohort of 2.3 million adolescents","volume":"39","author":"Twig","year":"2016","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B70","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","article-title":"Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood","volume":"374","author":"Twig","year":"2016","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B71","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ajcn\/83.4.767","article-title":"Association of body mass index measured in childhood, adolescence, and young adulthood with risk of ischemic heart disease and stroke: findings from 3 historical cohort studies","volume":"83","author":"Lawlor","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2026061714573851500_B72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1399-5448.2007.00336.x","article-title":"Impaired glucose tolerance and risk factors for progression to type 2 diabetes in youth","volume":"8","author":"Weiss","year":"2007","journal-title":"Pediatr Diabetes"},{"key":"2026061714573851500_B73","unstructured":"U.S. Food and Drug Administration\n          . FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes,2022. Accessed 31 July 2023. Available from https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/317b871#:\u02dc:text=Today%2C%20the%20U.S.%20Food%20and%20Drug%20Administration%20approved,diabetes%2C%20as%20an%20addition%20to%20diet%20and%20exercise"},{"key":"2026061714573851500_B74","unstructured":"U.S. Food and Drug Administration\n          . FDA Approves First Medication for Obstructive Sleep Apnea, 2024. Accessed 13 January 2025. Available from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea"},{"key":"2026061714573851500_B75","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061714573851500_B76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2026061714573851500_B77","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"2026061714573851500_B78","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/pedi.12763","article-title":"Eligibility for clinical trials is limited for youth with type 2 diabetes: insights from the Pediatric Diabetes Consortium T2D Clinic Registry","volume":"19","author":"Tamborlane","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2026061714573851500_B79","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jpeds.2016.06.059","article-title":"Utility of body mass index in identifying excess adiposity in youth across the obesity spectrum","volume":"177","author":"Ryder","year":"2016","journal-title":"J Pediatr"},{"key":"2026061714573851500_B81","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41390-024-03112-8","article-title":"Waist-circumference-to-height-ratio had better longitudinal agreement with DEXA-measured fat mass than BMI in 7237 children","volume":"96","author":"Agbaje","year":"2024","journal-title":"Pediatr Res"},{"key":"2026061714573851500_B82","doi-asserted-by":"crossref","DOI":"10.1093\/obendo\/wjaf002","article-title":"Body mass index triples overweight prevalence in 7600 children compared with waist-to-height ratio: the ALSPAC study","author":"Agbaje","year":"2025","journal-title":"Obesity and Endocrinology"},{"key":"2026061714573851500_B83","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.2337\/dc25-S014","article-title":"14. Children and adolescents: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-023-01501-7","article-title":"Youth-onset type 2 diabetes: burden of complications and socioeconomic cost","volume":"23","author":"Rodriquez","year":"2023","journal-title":"Curr Diab Rep"},{"key":"2026061714573851500_B85","doi-asserted-by":"crossref","first-page":"e2336400","DOI":"10.1001\/jamanetworkopen.2023.36400","article-title":"Cost-effectiveness of antiobesity drugs for adolescents with severe obesity","volume":"6","author":"Mital","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026061714573851500_B86","doi-asserted-by":"crossref","first-page":"e2329178","DOI":"10.1001\/jamanetworkopen.2023.29178","article-title":"Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents","volume":"6","author":"Lim","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026061714573851500_B87","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10198-022-01494-2","article-title":"Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations","volume":"24","author":"Jordan","year":"2023","journal-title":"Eur J Health Econ"},{"key":"2026061714573851500_B88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0145721717691146","article-title":"A qualitative study of cognitive, behavioral, and psychosocial challenges associated with pediatric type 2 diabetes in ethnic minority parents and adolescents","volume":"43","author":"St George","year":"2017","journal-title":"Diabetes Educ"},{"key":"2026061714573851500_B89","unstructured":"Robert Wood Johnson Foundation\n          . Coverage of obesity therapies in state-regulated markets: insights from a new data source, 2024. Accessed 8 April 2025. Available from https:\/\/www.rwjf.org\/en\/insights\/our-research\/2024\/08\/marketplace-pulse-coverage-of-obesity-therapies-in-state-regulated-markets.html"},{"key":"2026061714573851500_B90","unstructured":"Congress.gov\n          . H.R.4818 - Treat and Reduce Obesity Act of 2023 [article online], 2024. Accessed 8 April 2025. Available from https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/4818l"},{"key":"2026061714573851500_B91","unstructured":"Centers for Disease Control and Prevention\n          . Diabetes: Coexisting Conditions and Complications, 2022. Accessed 9 January 2023. Available from https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html#cdc_report_pub_study_section_8-coexisting-conditions-and-complications"},{"key":"2026061714573851500_B92","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","article-title":"Type 2 diabetes mellitus and hypertension: an update","volume":"43","author":"Lastra","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026061714573851500_B93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diabres.2005.03.032","article-title":"Prevalence and control of dyslipidemia among persons with diabetes in the United States","volume":"70","author":"Jacobs","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061714573851500_B94","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"2026061714573851500_B95","doi-asserted-by":"crossref","first-page":"e00321","DOI":"10.1002\/edm2.321","article-title":"DISCOVER investigators. Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: insights from the DISCOVER prospective cohort study","volume":"5","author":"Arnold","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026061714573851500_B96","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/dc11-0431","article-title":"Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study","volume":"34","author":"Anderson","year":"2011","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B97","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1464-5491.2006.01943.x","article-title":"The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Ali","year":"2006","journal-title":"Diabet Med"},{"key":"2026061714573851500_B98","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2337\/dc15-1206","article-title":"Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience","volume":"39","author":"Klingensmith","year":"2016","journal-title":"Diabetes Care"},{"key":"2026061714573851500_B99","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2026061714573851500_B100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/12\/1981\/837831\/dci250031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/12\/1981\/837831\/dci250031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:57:55Z","timestamp":1781722675000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/12\/1981\/163058\/Extinguishing-the-Fire-Treating-Pediatric-Type-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":100,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci25-0031","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}